west
africa
ebov
epidem
biggest
ebov
outbreak
date
analysi
virusspecif
tcell
immun
survivor
show
individu
respons
least
one
ebov
protein
domin
respons
subject
specif
ebov
nucleocapsid
protein
np
suggest
epitop
ebov
np
could
form
import
part
effect
tcell
vaccin
ebola
zair
show
peptid
yqvnnleei
locat
conserv
region
ebov
np
provid
protect
morbid
mortal
mous
adapt
ebov
challeng
singl
vaccin
mous
use
adjuv
microspher
peptid
vaccin
formul
contain
enough
confer
immun
mice
work
suggest
peptid
vaccin
base
tcell
immun
ebov
survivor
conceptu
sound
feasibl
nucleocapsid
protein
within
contain
multipl
class
epitop
predict
hla
restrict
consist
broad
popul
coverag
similar
approach
ctl
vaccin
design
may
possibl
viru
keyword
ebola
zair
vaccin
ctl
vaccin
control
yqvnnleei
flow
focus
develop
safe
effect
vaccin
virus
hiv
ebov
challeng
although
vaccin
develop
almost
exclus
focus
elicit
humor
immun
respons
host
inocul
whole
protein
antigen
ctl
peptid
vaccin
produc
tcell
respons
may
offer
import
altern
approach
hiv
ebov
influenza
particular
potenti
ctl
vaccin
discuss
although
comput
predict
alon
use
tcell
vaccin
design
saw
uniqu
opportun
see
prevent
ebov
tcell
vaccin
could
success
design
base
specif
epitop
target
survivor
document
ebov
infect
notion
hla
restrict
hiv
control
describ
pereyra
heckerman
conduct
analysi
virusspecif
tcell
immun
individu
live
hiv
report
hiv
control
individu
live
hiv
undergo
treatment
progress
aid
cell
target
differ
hla
restrict
class
epitop
hiv
compar
progressor
individu
hiv
progress
aid
absenc
therapi
pereyraheckerman
suggest
observ
could
guid
insilico
develop
ctl
vaccin
hiv
diseas
acquir
immun
document
ebov
infect
antibodi
well
tcell
respons
describ
sakeb
et
al
shown
subject
surviv
ebov
outbreak
west
africa
tcell
survivor
respond
least
one
ebov
antigen
respond
target
epitop
ebov
np
one
commonli
target
ebov
eptitop
ebov
np
survivor
group
target
cell
four
survivor
ipvyqvnnleeicqliiqaf
also
suggest
ctl
vaccin
could
design
use
epitop
target
tcell
identifi
ebov
control
human
pathogenderiv
peptid
antigen
also
recogn
tcell
previous
describ
includ
peptid
vesicular
stomat
viru
vsv
rgyvyqgl
human
immunodefici
viru
hiv
rgpgrafvti
exist
epitop
make
rang
pre
clinic
vaccin
experi
possibl
without
reli
nonhuman
primat
expens
complextomanag
human
mous
model
wilson
et
al
show
ebov
nucleoprotein
np
immunogen
provid
protect
ctlmediat
immun
ebov
mous
model
protect
confer
peptid
sequenc
within
ebola
zair
vyqvnnleeic
wilson
set
see
could
drive
ctl
expans
direct
occur
vaccin
mice
ebola
zair
vyqvnnleeic
subsequ
conduct
invivo
ebov
challeng
studi
see
peptid
protect
fabric
adjuv
microspher
studi
room
temperatur
stabl
dri
powder
use
flow
focus
process
diamet
prevent
one
microspher
phagocytos
given
antigen
present
cell
apc
time
load
one
peptid
sequenc
per
microspher
maxim
peptid
payload
mitig
possibl
multipl
differ
peptid
sequenc
deliv
apc
simultan
could
possibl
result
competit
inhibit
motif
could
interfer
antigen
present
subsequ
tcell
expans
supplementari
materi
section
also
set
see
similar
approach
ctl
vaccin
design
would
feasibl
base
analysi
hla
bind
characterist
peptid
sequenc
nucleocapsid
use
previous
describ
biodegrad
dri
powder
plga
microspher
synthet
vaccin
platform
adjuv
agonist
studi
articl
show
agonist
given
togeth
peptid
mous
model
produc
tcell
expans
elispot
microencapsul
peptid
ligand
ligand
inject
solut
requir
elicit
immun
respons
deliv
peptid
antigen
determin
elispot
studi
also
demonstr
microencapsul
peptid
alon
insuffici
induc
adequ
immun
respons
without
presenc
agonist
administ
describ
tlr
agonist
use
vaccin
formul
use
fda
approv
vaccin
sourc
nongmp
gmp
materi
preclin
clinic
studi
show
b
restrict
epitop
vsv
rgyvyqgl
ova
siinfekl
administ
mice
produc
use
adjuv
microspher
peptid
vaccin
platform
immun
mice
ctl
class
peptid
antigen
ebola
ziar
np
protein
identifi
protect
wilson
et
al
microspher
contain
cpg
prepar
dri
powder
formul
suspend
use
pb
inject
solut
contain
mpla
administ
intraderm
via
inject
base
tail
mice
describ
previou
public
illustr
figur
statist
signific
differ
elispot
data
vaccin
mice
versu
respons
seen
neg
elispot
control
wilson
report
protect
seen
experi
due
peptid
sequenc
within
hypothes
epitop
ineffici
process
mhc
bind
subsequ
antigen
present
order
explor
possibl
b
match
peptid
sequenc
contain
within
ebola
zair
vyqvnnleeic
prepar
three
peptid
vaccin
formul
contain
one
three
possibl
subsequ
within
sequenc
shown
tabl
vaccin
via
intraderm
tail
inject
three
group
mice
microspher
contain
one
three
subsequ
per
group
elispot
analysi
perform
stimul
harvest
splenocyt
three
possibl
subsequ
splenocyt
mice
receiv
subsequ
statist
higher
elispot
respons
mice
vaccin
two
possibl
subsequ
p
shown
figur
consist
predict
b
bind
affin
yqvnnleei
shown
supplementari
materi
tabl
load
one
popul
adjuv
microspher
peptid
predict
favor
b
bind
affin
shown
supplementari
materi
tabl
show
vaccin
mice
adjuv
microspher
vaccin
load
show
elispot
respons
wherea
mice
vaccin
adjuv
microspher
load
peptid
figur
also
show
mice
vaccin
alon
show
elispot
respons
figur
convers
mice
vaccin
show
respons
figur
conduct
pilot
studi
demonstr
intraperiton
inject
adjuv
microspher
vaccin
produc
statist
superior
immun
respons
elispot
compar
dose
deliv
intraderm
tail
intramuscular
inject
mice
supplementari
materi
section
base
data
studi
fact
volum
intraperiton
space
would
allow
larger
amount
microspher
suspens
deliv
chose
proceed
intraperiton
administr
challeng
portion
studi
deliv
microspher
per
dose
dose
three
group
mice
ten
mice
per
group
adjuv
mi
tabl
peak
mortal
across
group
test
seen
mice
challeng
pfu
maebov
versu
pb
buffer
control
shown
surviv
curv
saw
appear
innat
immun
respons
pfu
ebov
exposur
level
suggest
ebov
mediat
innat
immun
respons
stimul
adjuv
provid
evid
protect
effect
vaccin
use
adjuv
microspher
vaccin
reproduc
serum
sampl
sacrif
anim
expos
ebov
receiv
vaccin
quantit
assay
variou
cytokin
use
bioplex
plate
anim
unwit
demis
serum
sampl
collect
pearson
correl
analysi
perform
assess
relationship
specif
cytokin
level
surviv
result
shown
tabl
observ
low
level
surviv
mice
nhp
infect
ebov
determin
research
elev
level
plasma
serum
ebov
infect
human
also
shown
elev
level
elev
level
associ
increas
mortal
similarli
observ
low
level
gmcsf
survivor
elev
level
associ
fatal
ebov
infect
human
subject
human
survivor
ebov
found
low
level
circul
cytokin
elev
level
gmcsf
associ
fatal
human
expos
ebov
late
tcell
target
nucleocapsid
two
year
initi
infect
decid
investig
feasibl
design
peptid
vaccin
target
nucleocapsid
avail
protein
sequenc
obtain
ncbi
viral
genom
resourc
within
genbank
nih
genet
sequenc
databas
retriev
sequenc
process
use
multipl
sequenc
align
msa
via
clustal
nucleocapsid
phosphoprotein
nucleocapsid
phosphoprotein
sequenc
trim
everi
possibl
peptid
sequenc
dose
predict
valu
peptid
cross
referenc
actual
invitro
bind
measur
ident
peptid
data
avail
prevent
vaccin
design
elicit
humor
immun
respons
typic
via
administr
whole
protein
pathogen
antibodi
antigen
hla
restrict
natur
ctl
vaccin
limit
util
protect
individu
infecti
diseas
howev
observ
deriv
individu
abl
control
hiv
infect
ebov
infect
demonstr
control
may
associ
specif
ctl
target
behavior
suggest
may
import
role
hlarestrict
pep
ebov
caus
sever
pulmonari
problem
expos
subject
problem
especi
sever
viru
deliv
aerosol
interact
ebov
specif
antibodi
nhp
lung
tissu
ebov
deliv
nhp
via
aerosol
produc
lethal
effect
nhp
without
circul
antiebov
antibodi
expos
aerosol
ebov
unpublish
confer
present
suggest
ctl
vaccin
may
effect
prophylaxi
filoviru
protect
antibodi
vaccin
anticip
rout
ebov
exposur
via
aerosol
coprotein
present
surfac
show
high
degre
conserv
epitop
within
intern
protein
often
stimul
tcellmedi
immun
respons
result
vaccin
stimul
influenza
specif
tcell
immun
consid
candid
univers
influenza
vaccin
respons
nucleocapsid
two
year
infect
suggest
approach
could
appli
con
tabl
supplementari
materi
tabl
remain
peptid
list
could
also
qualifi
potenti
vaccin
candid
confirm
mhc
bind
predict
invitro
bind
affin
andor
bind
stabil
studi
anoth
approach
evalu
candid
vaccin
peptid
though
invitro
test
also
possibl
shown
paper
peptid
target
ebov
control
could
form
basi
prevent
vaccin
ebov
elispot
analysi
pbmc
taken
peripher
blood
control
progressor
assess
presenc
differenti
respons
peptid
could
lead
broadli
applic
protect
ctl
vaccin
incorpor
peptid
vaccin
commonli
target
attack
control
versu
progressor
peptid
vaccin
unlik
typic
antibodi
vaccin
limit
viru
surfac
antigen
target
provid
opportun
attack
target
besid
spike
may
prone
mutat
addit
peptid
vaccin
mitig
risk
antibodi
diseas
enhanc
ade
seen
context
nonneutr
antibodi
respons
whole
protein
vaccin
also
neutral
antibodi
direct
spike
protein
patient
associ
increas
risk
acut
lung
injuri
ali
specif
patient
succumb
found
develop
neutral
antibodi
nab
respons
spike
protein
faster
survivor
onset
symptom
nab
titer
higher
patient
die
compar
recov
extent
antibodi
vaccin
produc
antibodi
respons
spike
protein
could
increas
risk
ali
risk
could
also
mitig
use
peptid
vaccin
altern
approach
extent
outbreak
allow
mani
control
identifi
thirti
individu
studi
sakab
seven
individu
identifi
peng
studi
furthermor
sakeb
peng
report
progressor
data
perhap
difficulti
obtain
blood
sampl
patient
research
act
outbreak
perhap
control
progressor
blood
sampl
could
collect
prospect
analyz
quickli
creat
databas
optim
candid
class
peptid
inclus
ctl
vaccin
potenti
broad
hla
coverag
subsequ
rapid
manufactur
deploy
would
interest
see
extent
peptid
favor
control
appear
nucleocapsid
make
second
exampl
across
two
differ
virus
control
exhibit
ctl
attack
preferenti
nucleocapsid
protein
anim
handl
done
accord
nih
institut
